SCHEMBL23212045

SCHEMBL23212045

CC(C)(C)OC(=O)N1CC(C(OCC(F)(F)F)c2ccc(F)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TACR1 P25103 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RORC P51449 3/20 0.40
MMP13 P45452 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
BACE1 P56817 2/20 0.38
FAAH O00519 1/20 0.38
MGLL Q99685 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21381989 1.00 LIPE (0.41) LIPEHDAC1HDAC2TACR1MEN1
SCHEMBL21384762 0.89 MMP13 (0.49) MEN1KMT2AMMP13GPR119NPC1
SCHEMBL23211893 0.89 MMP13 (0.49) MEN1KMT2AMMP13GPR119NPC1
SCHEMBL21381935 0.84 EPHX2 (0.39) TACR1MEN1KMT2AFAAHMGLL
SCHEMBL23211960 0.84 EPHX2 (0.39) TACR1MEN1KMT2AFAAHMGLL
SCHEMBL29068343 0.83 HDAC1 (0.41) HDAC1HDAC2TACR1MEN1KMT2A
SCHEMBL23211978 0.79 HDAC1 (0.46) HDAC1HDAC2MEN1KMT2ARORC
SCHEMBL21384664 0.79 HDAC1 (0.46) HDAC1HDAC2MEN1KMT2ARORC
SCHEMBL21381700 0.79 EPHX2 (0.35) TACR1MEN1KMT2AFAAHMGLL
SCHEMBL16232117 0.78 HDAC2 (0.47) HDAC1HDAC2MEN1KMT2ARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885HDAC1 919/4885HDAC2 2508/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885HDAC1 919/4885HDAC2 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.